Affiliations 

  • 1 School of Pharmacy, Monash University Malaysia, Bandar Sunway, Malaysia
  • 2 Nutrition Unit, Malaysian Palm Oil Board, Bandar Baru Bangi, Malaysia
  • 3 Medical Technology Division, Malaysian Nuclear Agency, Bangi, Malaysia
  • 4 Department of Pharmacy, Fatima College of Health Sciences, Al Ain, United Arab Emirates
Front Pharmacol, 2021;12:778396.
PMID: 35069200 DOI: 10.3389/fphar.2021.778396

Abstract

The purpose of this work was to study the biodistribution of niosomes in tumor-implanted BALB/c mice using gamma scintigraphy. Niosomes were first formulated and characterized, then radiolabeled with Technetium-99 m (99mTc). The biodistribution of 99mTc-labeled niosomes was evaluated in tumor-bearing mice through intravenous injection and imaged with gamma scintigraphy. The labeled complexes possessed high radiolabeling efficiency (98.08%) and were stable in vitro (>80% after 8 h). Scintigraphic imaging showed negligible accumulation in the stomach and thyroid, indicating minimal leaching of the radiolabel in vivo. Radioactivity was found mainly in the liver, spleen and kidneys. Tumor-to-muscle ratio indicated a higher specificity of the formulation for the tumor area. Overall, the formulated niosomes are stable both in vitro and in vivo, and show preferential tumor accumulation.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.